Regeneron Pharmaceuticals Inc. buy Cantor Fitzgerald
Start price
02.02.26
/
50%
€642.80
Target price
02.02.27
€673.76
Performance (%)
3.39%
Price
06.02.26
€664.60
Summary
This prediction is currently active. With a performance of 3.39%, the BUY prediction by Cantor_Fitzgerald for Regeneron Pharmaceuticals Inc. is trending in the right direction. This prediction currently runs until 02.02.27. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Regeneron Pharmaceuticals Inc. | 3.39% |
| iShares Core DAX® | 1.085% |
| iShares Nasdaq 100 | -1.665% |
| iShares Nikkei 225® | 3.863% |
| iShares S&P 500 | 0.111% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Cantor Fitzgerald from $740.00 to $800.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Stopped prediction by Cantor_Fitzgerald for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€558.60
29.10.25
29.10.25
€635.29
29.10.26
29.10.26
19.13%
06.02.26
06.02.26
